Download PDF
Pharmacopsychiatry 1999; 32: 44-48
DOI: 10.1055/s-2007-979236
Original Papers

© Georg Thieme Verlag Stuttgart · New York

Piracetam and Platelets

A Review of Laboratory and Clinical DataS. Evers, K.-H. Grotemeyer
  • Department of Neurology, University of Münster, Münster, Germany and Department of Neurology, Saarbrücker Winterbergkliniken GmbH, Saarbrücken, Germany
Further Information

Publication History

Publication Date:
20 April 2007 (online)

Also available at
  PDF Download  Permissions and Reprints

Abstract

This paper reviews the effects of piracetam on platelet function and the evidence for its antiplatelet effect which is mediated mainly by inhibition of platelet aggregation. Piracetam also possesses antithrombotic activity in vivo. It has been shown to normalize platelet aggregation in patients with increased platelet aggregability in various disorders including acute stroke, transient cerebral ischemic attacks and diabetes mellitus. This, together with clinical improvement, has also been shown in patients with Raynaud's phenomenon. The results of recent studies are presented in which piracetam showed similar efficacy to aspirin in the secondary prophylaxis of ischemic stroke.

      >